These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 33362435)

  • 1. The effects of COVID-19 on IBD prescribing and service provision in a UK tertiary centre.
    Sharma E; Meade S; D'Errico F; Pavlidis P; Luber R; Zeki S; Hill K; Duff A; O'Hanlon D; Tripoli S; Stanton A; Caracostea A; Honap S; Reynolds R; Anderson S; Ray S; Mawdsley J; Sanderson J; Samaan MA; Irving PM
    GastroHep; 2020 Nov; 2(6):318-326. PubMed ID: 33362435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of comorbidities on treatment considerations for first-line biologic prescribing in patients with inflammatory bowel disease in the UK.
    Akbar A; Orchard T; Powell N; Selinger C; Tibbatts C
    Frontline Gastroenterol; 2022; 13(6):490-496. PubMed ID: 36250175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inflammatory Bowel Disease Management in a Romanian Tertiary Gastroenterology Center: Challenges of the COVID-19 Pandemic.
    Vadan R; Iacob R; Costache R; Stroie T; Saizu IA; Iacob S; Gheorghe L; Diculescu M; Gheorghe C
    J Gastrointestin Liver Dis; 2020 Dec; 29(4):549-553. PubMed ID: 33331349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study.
    Liu Z; Le K; Zhou X; Alexander JL; Lin S; Bewshea C; Chanchlani N; Nice R; McDonald TJ; Lamb CA; Sebastian S; Kok K; Lees CW; Hart AL; Pollok RC; Boyton RJ; Altmann DM; Pollock KM; Goodhand JR; Kennedy NA; Ahmad T; Powell N;
    Lancet Gastroenterol Hepatol; 2023 Feb; 8(2):145-156. PubMed ID: 36481043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of a pharmacist-led thiopurine monitoring service in outpatients with inflammatory bowel disease.
    Rodda SE; Fildes KJ; Shelton E; Goldberg R; Moore GT
    Intern Med J; 2023 May; 53(5):779-786. PubMed ID: 35603759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prior Immunogenicity to Anti-TNF Biologics Is Not Associated with Increased Anti-drug Antibodies to Vedolizumab or Ustekinumab.
    Costable NJ; Borman ZA; Ji J; Dubinsky MC; Ungaro RC
    Dig Dis Sci; 2022 Jun; 67(6):2480-2484. PubMed ID: 34021427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 Vaccine Hesitancy among Patients with Inflammatory Bowel Disease Receiving Biologic Therapies in Kuwait: A Cross-Sectional Study.
    Shehab M; Zurba Y; Al Abdulsalam A; Alfadhli A; Elouali S
    Vaccines (Basel); 2021 Dec; 10(1):. PubMed ID: 35062716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of COVID-19 pandemic on the management of paediatric inflammatory bowel disease: An Italian multicentre study on behalf of the SIGENP IBD Group.
    Arrigo S; Alvisi P; Banzato C; Bramuzzo M; Celano R; Civitelli F; D'Arcangelo G; Dilillo A; Dipasquale V; Felici E; Fuoti M; Gatti S; Knafelz D; Lionetti P; Mario F; Marseglia A; Martelossi S; Moretti C; Norsa L; Panceri R; Renzo S; Romano C; Romeo E; Strisciuglio C; Martinelli M
    Dig Liver Dis; 2021 Mar; 53(3):283-288. PubMed ID: 33388247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Outcomes and Safety of Vedolizumab vs Tumor Necrosis Factor Antagonists for Older Adults With Inflammatory Bowel Diseases.
    Singh S; Iversen AT; Allin KH; Jess T
    JAMA Netw Open; 2022 Sep; 5(9):e2234200. PubMed ID: 36178685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P022 Biologic Therapy and Therapeutic Drug Monitoring in Patients With Inflammatory Bowel Disease and Primary Sclerosing Cholangitis.
    Jain V; Behm B; Figueroa E
    Am J Gastroenterol; 2021 Dec; 116(Suppl 1):S5. PubMed ID: 37461942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. React, reset and restore: Adaptation of a large inflammatory bowel disease service during COVID-19 pandemic.
    Gonzalez HA; Myers S; Whitehead E; Pattinson A; Stamp K; Turnbull J; Fory R; Featherstone B; Wilkinson A; Lisle J; Haire G; Henderson E; Sebastia S
    Clin Med (Lond); 2020 Sep; 20(5):e183-e188. PubMed ID: 32719036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expanding telehealth options during the COVID pandemic eliminated racial and age disparities in electronic communication by inflammatory bowel disease patients.
    Hayrapetian L; Zepp M; Rao S; Hennessey M; Houle M; Atienza M; Belfaqeeh OA; Dharia I; Khan A; Borum ML
    J Natl Med Assoc; 2021 Aug; 113(4):474-477. PubMed ID: 33941370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P074 Comparative Risk of Clostridioides Difficile Infection in Vedolizumab vs anti-TNFa Agents in Biologic-Naïve Patients With Ulcerative Colitis.
    Dalal R; Mitri J; Goodrick H; Allegretti J
    Am J Gastroenterol; 2021 Dec; 116(Suppl 1):S19. PubMed ID: 37461990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study.
    Alexander JL; Liu Z; Muñoz Sandoval D; Reynolds C; Ibraheim H; Anandabaskaran S; Saifuddin A; Castro Seoane R; Anand N; Nice R; Bewshea C; D'Mello A; Constable L; Jones GR; Balarajah S; Fiorentino F; Sebastian S; Irving PM; Hicks LC; Williams HRT; Kent AJ; Linger R; Parkes M; Kok K; Patel KV; Teare JP; Altmann DM; Goodhand JR; Hart AL; Lees CW; Boyton RJ; Kennedy NA; Ahmad T; Powell N;
    Lancet Gastroenterol Hepatol; 2022 Nov; 7(11):1005-1015. PubMed ID: 36088954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vedolizumab does not increase risk of clostridium difficile infection in patients with inflammatory bowel disease using vedolizumab: A retrospective cohort study.
    Saad Alshahrani A; Mohammad D; Attieh Alzahrani M; Narula N
    Saudi Pharm J; 2023 Sep; 31(9):101736. PubMed ID: 37638216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of vedolizumab and ustekinumab as second biologic agent in achieving target outcomes in tumor necrosis factor antagonists experienced patients with inflammatory bowel disease (enroll-ex study).
    Alrashed F; Abdullah I; Alfadhli A; Shehab M
    Front Pharmacol; 2023; 14():1243080. PubMed ID: 37876726
    [No Abstract]   [Full Text] [Related]  

  • 17. Organisational changes and challenges for inflammatory bowel disease services in the UK during the COVID-19 pandemic.
    Kennedy NA; Hansen R; Younge L; Mawdsley J; Beattie RM; Din S; Lamb CA; Smith PJ; Selinger C; Limdi J; Iqbal TH; Lobo A; Cooney R; Brain O; Gaya DR; Murray C; Pollok R; Kent A; Raine T; Bhala N; Lindsay JO; Irving PM; Lees CW; Sebastian S
    Frontline Gastroenterol; 2020; 11(5):343-350. PubMed ID: 32874484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of COVID-19 on diagnosis and management of paediatric inflammatory bowel disease during lockdown: a UK nationwide study.
    Ashton JJ; Kammermeier J; Spray C; Russell RK; Hansen R; Howarth LJ; Torrente F; Deb P; Renji E; Muhammed R; Paul T; Kiparissi F; Epstein J; Lawson M; Hope B; Zamvar V; Narula P; Kadir A; Devadason D; Bhavsar H; Beattie RM
    Arch Dis Child; 2020 Dec; 105(12):1186-1191. PubMed ID: 32732316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A more frequent disease monitorering but no increased disease activity in patients with inflammatory bowel disease during the first year of the SARS-CoV-2 pandemic. A retrospective study.
    Lindhagen S; Karling P
    Scand J Gastroenterol; 2022 Feb; 57(2):169-174. PubMed ID: 34699290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of Immunomodulator Use as Combination Therapy With Vedolizumab or Ustekinumab in Inflammatory Bowel Disease.
    Lutz M; Caldera F; Schroeder K; Gazis D; Crawford JM; Long MD; Barnes EL
    Clin Transl Gastroenterol; 2023 Nov; 14(11):e00620. PubMed ID: 37450671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.